• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by LianBio

    3/12/24 7:56:56 AM ET
    $LIAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIAN alert in real time by email
    POS AM 1 lianbio-sx3posam.htm POS AM Document

    As filed with the Securities and Exchange Commission on March 12, 2024
    Registration No. 333-268317
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    POST-EFFECTIVE AMENDMENT NO. 1 (NO. 333-268317)
    TO
    FORM S-3
    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933
    LIANBIO
    (Exact name of registrant as specified in its charter)
    Cayman Islands
    98-1594670
    (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    103 Carnegie Center Drive, Suite 309
    Princeton, NJ 08540
    (609) 486-2308
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
    Adam Stone
    LianBio
    103 Carnegie Center Drive, Suite 309
    Princeton, NJ 08540
    (609) 486-2308
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    With a copy to:
    Thomas J. Danielski
    Ropes & Gray LLP
    800 Boylston Street
    Boston, Massachusetts 02199
    (617) 951-7000
    Approximate date of commencement of proposed sale to the public: Not applicable.
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer  ☐
    Accelerated filer  ☐
    Non-accelerated filer  ☒
    Smaller reporting company  ☒
    Emerging growth company  ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒



    EXPLANATORY NOTE/DEREGISTRATION OF SECURITIES
    LianBio, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“LianBio” or the “Company”), is filing this post-effective amendment (the “Post-Effective Amendment”) to the following Registration Statement on Form S-3 (the “Registration Statement”), which has been previously filed with the Securities and Exchange Commission (the “SEC”), to deregister:
    1.Any and all securities, registered but unsold or otherwise unissued as of the date hereof under the Registration Statement on Form S-3 (File No. 333-268317), filed with the SEC on November 10, 2022, as amended by Amendment No. 1 to the Registration Statement, filed with the SEC on December 9, 2022, as further amended by Amendment No. 2 to the Registration Statement, filed with the SEC on March 29, 2023, and as further amended by Amendment No. 3 to the Registration Statement, filed with the SEC on April 26, 2023, registering an indeterminate number of Ordinary Shares in the form of ordinary shares or American Depositary Shares (“ADSs”), par value $0.000017100448 (the “Ordinary Shares”), Preferred Shares in the form of preferred shares or ADSs, Debt Securities, Warrants, Units, or any combination of the foregoing, having an aggregate initial public offering price not to exceed $500 million.
    On February 13, 2024, the Company announced its intention to apply for the voluntary delisting of the its ADSs, each representing the right to receive one Ordinary Share, from the Nasdaq Global Market and the voluntary deregistration from the reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with the SEC. In connection with the Company’s voluntary decision to delist and deregister, the Company has terminated any and all offerings pursuant to the Registration Statement. Accordingly, this filing is made pursuant to an undertaking made by the Company in Part II of the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering. The Company, by filing this Post-Effective Amendment, hereby terminates the effectiveness of the Registration Statement and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statement as of the date hereof.



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, State of New Jersey on March 12, 2024.
    LIANBIO
    By:/s/ Adam Stone
    Name:Adam Stone
    Title:Interim Chief Executive Officer
    No other person is required to sign the Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.

    Get the next $LIAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIAN

    DatePrice TargetRatingAnalyst
    1/3/2024$5.00 → $3.00Buy → Underperform
    BofA Securities
    12/22/2023$7.00 → $4.00Buy → Hold
    Jefferies
    More analyst ratings

    $LIAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LianBio downgraded by BofA Securities with a new price target

      BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously

      1/3/24 7:58:41 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio downgraded by Jefferies with a new price target

      Jefferies downgraded LianBio from Buy to Hold and set a new price target of $4.00 from $7.00 previously

      12/22/23 7:26:46 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by LianBio (Amendment)

      SC 13D/A - LianBio (0001831283) (Subject)

      2/29/24 7:45:48 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by LianBio

      SC 13D - LianBio (0001831283) (Subject)

      11/30/23 5:08:48 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by LianBio

      SC 13G - LianBio (0001831283) (Subject)

      11/1/23 4:00:16 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    SEC Filings

    See more
    • SEC Form 15-12G filed by LianBio

      15-12G - LianBio (0001831283) (Filer)

      3/21/24 8:00:10 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by LianBio

      EFFECT - LianBio (0001831283) (Filer)

      3/13/24 12:15:04 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-6 POS filed by LianBio

      F-6 POS - LianBio (0001831283) (Subject)

      3/12/24 8:30:54 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Financials

    Live finance-specific insights

    See more
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients

      • Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review EXPLORER-CN topline data and the China market opportunity for mavacamten on Monday, May 1 at 8:00 a.m. EDT / 8:00 p.m. CST SHANGHAI, China and PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to pati

      4/26/23 8:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gu Ehong sold $7,513 worth of Ordinary Shares (1,731 units at $4.34) and returned $5,724 worth of Ordinary Shares to the company (17,889 units at $0.32), closing all direct ownership in the company (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      4/11/24 4:10:11 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Poukalov Konstantin exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      2/20/24 5:27:03 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc exercised 72,600 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 38,436 units of Ordinary Shares (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      2/20/24 5:25:28 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Appoints Wei Wei Chen to Board of Directors

      SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company's Board of Directors. "I am pleased to welcome Wei Wei Chen to the LianBio board," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "Her deep knowledge of the Chinese market, combined with her ability to manage business growth and transformation, will be extremely beneficial to LianBio as we grow our team and make strides toward advancing our diverse pipeline of potentially transformative medicines for patients

      4/7/22 8:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care